Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections
- PMID: 27319273
- DOI: 10.1016/j.ijantimicag.2016.05.003
Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections
Abstract
An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log10 copies/mL [βinteraction -0.071, standard error (SE) 0.121, 95% confidence interval (CI) -0.309 to 0.167]; culture-negative, 94% (vs. 95%); and RNA-negative, 44% (vs. 36%). Extended treatment of >5 days was required in 69% of cases because of slow clinical resolution and viral clearance in LRTCs. Peramivir was well tolerated. These data are useful for future trial design in this unique population.
Keywords: Influenza; Lower respiratory tract complications; Peramivir.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Similar articles
-
Intravenous peramivir for treatment of influenza in hospitalized patients.Antivir Ther. 2014;19(4):349-61. doi: 10.3851/IMP2680. Epub 2013 Aug 28. Antivir Ther. 2014. PMID: 23985625 Clinical Trial.
-
Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.Antivir Ther. 2015;20(7):709-19. doi: 10.3851/IMP2874. Epub 2014 Oct 15. Antivir Ther. 2015. PMID: 25318121
-
Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.Clin Infect Dis. 2011 Mar 15;52(6):695-706. doi: 10.1093/cid/cir001. Clin Infect Dis. 2011. PMID: 21367722 Free PMC article.
-
Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.Yonsei Med J. 2017 Jul;58(4):778-785. doi: 10.3349/ymj.2017.58.4.778. Yonsei Med J. 2017. PMID: 28540991 Free PMC article. Review.
-
Peramivir: A Review in Uncomplicated Influenza.Drugs. 2018 Sep;78(13):1363-1370. doi: 10.1007/s40265-018-0981-8. Drugs. 2018. PMID: 30196350 Review.
Cited by
-
A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.Respirology. 2017 Oct;22(7):1300-1312. doi: 10.1111/resp.13114. Epub 2017 Jul 5. Respirology. 2017. PMID: 28677861 Free PMC article. Review.
-
Severe flu management: a point of view.Intensive Care Med. 2020 Feb;46(2):153-162. doi: 10.1007/s00134-019-05868-8. Epub 2020 Jan 7. Intensive Care Med. 2020. PMID: 31912206 Free PMC article. Review.
-
Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials.Adv Ther. 2020 Jun;37(6):2646-2666. doi: 10.1007/s12325-020-01347-5. Epub 2020 Apr 28. Adv Ther. 2020. PMID: 32347523 Free PMC article.
-
Evaluating the impact of school-based influenza vaccination programme on absenteeism and outbreaks at schools in Hong Kong: a retrospective cohort study protocol.J Health Popul Nutr. 2024 May 10;43(1):62. doi: 10.1186/s41043-024-00561-z. J Health Popul Nutr. 2024. PMID: 38730508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical